Inotek Pharmaceuticals
Lexington
About Inotek Pharmaceuticals
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $125.9M
- Funding stage: M&A
- Last round: Series Unknown (Sep 2013)
- Ticker: nasdaq:ITEK
- Website: inotekcorp.com
- Phone: 7816762115
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical
Canonical: https://fsome.com/organization/inotek-pharmaceuticals-787744 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.